We report more exciting news about the Immunoscore® diagnostic tool developed by our partners at HalioDx!
The immuno-oncology diagnostic company, HalioDx announced last week that it has entered into a Collaboration Agreement with the FFCD, the French Cooperative Group dedicated exclusively to digestive oncology, on the Phase II multi-center POCHI trial (FFCD1703 – NCT04262687) in which immune response at the tumour site will be used to inform patient eligibility to participate in the POCHI trial. The aim of this trial is to evaluate the efficacy of pembrolizumab in combination with XELOX (capecitabine plus oxaliplatin) and bevacizumab as first-line treatment of microsatellite stable (MSS)/proficient mismatch repair system (pMMR) metastatic colorectal cancer (mCRC) with high immune infiltrate.
Immune Checkpoint Inhibitors (ICIs) have demonstrated high efficacy in mCRC with microsatellite instability (MSI)/deficient mismatch repair system (dMMR) but remain ineffective alone in MSS/pMMR tumours. MSS/pMMR tumours presenting a high immune infiltrate as assessed by Immunoscore® could be sensitive to ICI therapy. The POCHI trial will prospectively enrol about 400 patients with the goal of testing the combination on 55 patients with an MSS/pMMR mCRC with a high immune response (≈15%).
“The POCHI study is crucial to determine whether tumor immune response assessment can help identifying MSS/pMMR mCRC patients eligible for ICI in combination with chemotherapy plus anti-angiogenic. We believe that this study will lead to a phase III trial to evaluate ICI combination in patients with an MSS/pMMR mCRC with a high immune score.” commneted David Tougeron, MD, PhD at Poitiers University Hospital in France, Principal Investigator of the POCHI trial.
Read the original press release from HalioDx here.
Within COLOSSUS, HalioDx works with a team to complete the biorepository and histopathology analyses. In addition, they work to develop a customized Next Generation Sequencing (NGS) companion diagnostic test. Once established, the COLOSSUS classifiers will be translated into a targeted NGS assay to enable fast and efficient determination of the COLOSSUS clusters.
Watch our short video to learn more about the COLOSSUS project and our clinical study: https://www.youtube.com/watch?v=-Zxym7__7yA&feature=youtu.be